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Abstract 1 
Epigenetic mechanisms might play a role in the pathophysiology of hypertension, 2 
a major risk factor for cardiovascular disease and renal failure. We aimed to 3 
systematically review studies investigating the association between epigenetic 4 
marks (global, candidate-gene or genome-wide methylation of DNA and histone 5 
modifications) and blood pressure or hypertension. Five bibliographic databases 6 
were searched until the 7th of December 2018. Of 2,984 identified references, 26 7 
articles based on 25 unique studies met our inclusion criteria, which involved a 8 
total of 28,382 participants. The five studies that assessed global DNA-9 
methylation, generally found lower methylation levels with higher systolic blood 10 
pressure, diastolic blood pressure and/or presence of hypertension. Eighteen 11 
candidate-gene studies reported, in total, 16 differentially methylated genes 12 
including renin-angiotensin-system related genes (ACE promoter, and AGTR1) 13 
and genes involved in sodium homeostasis and extracellular fluid volume 14 
maintenance system (NET promoter, SCNN1A, and ADD1). Between the three 15 
identified epigenome-wide association studies (EWAS), lower methylation levels 16 
of SULF1, EHMT2, and SKOR2 were found in hypertensive patients as compared 17 
to normotensive subjects and lower methylation levels of PHGDH, SLC7A11 and 18 
TSPAN2, were associated with higher systolic and diastolic blood pressure. In 19 
summary, the most convincing evidence has been reported from candidate-gene 20 
studies, which show reproducible epigenetic changes in the interconnected renin-21 
angiotensin and inflammatory systems. Our study highlights gaps in the literature 22 
on the role of histone modifications in blood pressure and the need to conduct 23 
high-quality studies, in particular, hypothesis-generating studies that may help to 24 
elucidate new molecular mechanisms. 25 
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Introduction 1 
Hypertension is a long-term condition in which the blood pressure (BP) in the 2 
arteries is persistently elevated. The burden of hypertension remains increasing 3 
despite the availability of effective medication, as well as the outcomes 4 
associated with it, such as ischemic heart disease, cerebrovascular disease and 5 
chronic kidney disease (1, 2).  6 
The aetiology of hypertension remains unclear, therefore, a better understanding 7 
of the risk factors is key to improve prevention strategies. Several environmental 8 
risk factors are contributing to hypertension (3-5). Genetic variants also 9 
determine BP and the risk of hypertension, which heritability has been estimated 10 
to be up to 30-50% (6). The most recent genome-wide association study (GWAS) 11 
on blood pressure phenotypes was conducted among 321,262 participants and 12 
found more than 241 loci, of which 44 were newly discovered. This study and 13 
previous genetic investigation of the biology of blood pressure regulation, have 14 
revealed new opportunities for future drug development and highlighted the 15 
shared genetic architecture between blood pressure and lifestyle exposures such 16 
as obesity, smoking, alcohol and high salt-intake (7-9). However, these variants 17 
explain only a minor fraction (<5%) of the inter-individual variation in the 18 
susceptibility for hypertension (10). 19 
Epigenetic modifications might contribute to the pathophysiology of hypertension 20 
(11). Epigenetics refers to dynamic and potentially reversible changes that alter 21 
gene activity and expression. DNA methylation and histone modifications are the 22 
most studied epigenetic mechanisms and have been involved in pathways 23 
Epigenetics and blood pressure: systematic review ⋯ 
4 
 
related to dyslipidaemia, type 2 diabetes, and cardiovascular disease, conditions 1 
that are strongly correlated with hypertension (11-13).  2 
To date, however, little work has been done to systematically assess the current 3 
evidence of the role epigenetic modifications on the risk of high blood pressure. 4 
We aimed to systematically review all the available evidence of the association 5 
epigenetics with high blood pressure. A critical appraisal of limitations and gaps 6 
in the field is also presented.  7 
Methods 
Literature search 8 
This review was conducted and reported in accordance with the PRISMA (14) 9 
guideline (Appendix S1). We sought studies published before the 7th of 10 
December 2018 (date last searched) in five electronic databases: Embase.com, 11 
Medline (Ovid), Web-of-Science, Cochrane Central and Google Scholar. The 12 
search was done with the help of a medical information specialist.  In databases 13 
where a thesaurus was available (Embase and Medline), articles were searched 14 
by thesaurus terms, title and/or abstract. In other databases, only by title and/or 15 
abstract. The search combined terms related to the exposure (e.g. epigenetic, 16 
histone acetylation, methylation, demethylation, hypomethylation, 17 
hypermethylation, DNA methylation) and outcome (e.g. blood pressure, and 18 
hypertension). We did not apply any language restriction, but we restricted the 19 
search to studies conducted on humans. The full search strategies of all 20 
databases are provided in Appendix S2. The study identification also included 21 
manual search, based on the screening of the citations of the included studies.  22 
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Study selection and inclusion criteria 1 
Studies were eligible for inclusion if they (1) were cross-sectional studies, case-2 
control studies, or cohort studies; (2) were conducted among humans; (3) 3 
assessed epigenetic marks (global, site specific or genome-wide methylation of 4 
DNA or histone modifications); (4) collected data on blood pressure (systolic and 5 
diastolic blood pressure, hypertension, essential hypertension), and (5) reported 6 
the association of any of the above-mentioned epigenetic marks with blood 7 
pressure. We did not make restriction on the tissue examined for epigenetic 8 
marks. We excluded studies that examined epigenetic marks other than DNA 9 
methylation and histone modifications, such as noncoding RNAs. We also 10 
excluded post-mortem studies.  11 
Two independent reviewers conducted an initial screening of all titles and 12 
abstracts and then evaluated all potentially relevant articles based on full text 13 
reviews. If no consensus was reached, a third independent reviewer solved 14 
discrepancies between the two reviewers. 15 
Data extraction 16 
A predesigned data collection form was prepared to extract the relevant 17 
information from the selected studies, including study design, characteristics of 18 
the study population, location of the study, sample size, and degree of 19 
adjustment. Furthermore, we extracted, for each study, the tissue type and 20 
methods used to determine DNA methylation, the specific CpGs sites, the 21 
directions of the associations, and, when possible, the reported measures of 22 
associations (e.g., correlation coefficients, beta-coefficients, relative risks, and 23 
confidence intervals).  24 
Epigenetics and blood pressure: systematic review ⋯ 
6 
 
Assessing the risk of bias 1 
Two reviewers independently rated the quality of the studies based on the 2 
Newcastle-Ottawa Scale (NOS) (15), a semi-quantitative scale designed to 3 
evaluate the quality of case-control or cohort studies. We evaluated cross-4 
sectional studies using an adapted version of the scale. Studies that received a 5 
score of nine stars were judged to have good quality and to be at low risk of bias; 6 
studies that scored eight or seven stars were considered medium risk of bias and 7 
those that scored less than seven were considered to be at high risk of bias. 8 
Outcome assessment and statistical methods 9 
For each study, we defined whether an association was reported, and when 10 
applicable, direction and effect sizes were reported. Heterogeneity permitting, we 11 
sought to pool the results using a random effects meta-analysis model. However, 12 
due to differences in exposure and outcomes, and input parameters, it was not 13 
feasible to pool the data quantitatively. 14 
Results 15 
In total, we identified 2,984 unique references (Fig 1). Based on the title and 16 
abstract, we selected full texts of 55 articles for detailed evaluation. After full-text 17 
assessment, 26 of these articles, based on 25 unique studies, met our eligibility 18 
criteria and were included in this review. The other 29 articles were excluded for 19 
reasons presented in Fig 1. 20 
Characteristics of the included studies 21 
Detailed characteristics of the 25 included studies are summarized in Tables 1-22 
3. Combined, the 25 studies included data from 28,382 individuals. Five studies 23 
assessed global DNA-methylation. From those, two studies also used candidate-24 
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gene approach (16, 17). Sixteen studies assessed the DNA methylation only in 1 
specific candidate genes, three studies used genome-wide approaches, and one 2 
study assessed histone modification in relation to BP. One study included South 3 
Asian and European population (18), and another one included individuals of 4 
European, African American, and Hispanic ancestry from different countries. 5 
Twelve studies included participants from China, three from Canada, two from 6 
USA, and the rest included participants from Brazil, Egypt, the Netherlands, 7 
Poland, Spain and Switzerland. The majority (n=22) of the studies assessed 8 
epigenetic signatures in blood, two in visceral adipose tissue (VAT) and one in 9 
saliva. Eight studies were judged to be at medium risk of bias whereas the rest 10 
at high risk of bias. 11 
Outcome definition and assessment 12 
The studies reported the outcomes in two different ways: measures of blood 13 
pressure (expressed as continuous variables) (n=7) or diagnosis status 14 
(presence or absence of essential hypertension) (n=14). The remaining four 15 
studies reported both types of outcomes. Although studies that reported 16 
diagnosis status, used different cut-off to define the presence of essential 17 
hypertension, the majority (n=11) used the same criteria based on the 18 
European Society of Hypertension-European Society of Cardiology Guidelines 19 
of 2003 (19) (Table S3). Studies that assessed the blood pressure levels, 20 
usually measured it in a standardized way. That is after at least 10 minutes of 21 
rest, with multiple measures taken with waiting intervals of 10 minutes between 22 
them, either in different days or in different arms, in order to finally obtain an 23 
average measure (Table S3). 24 
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Global DNA methylation and blood pressure 1 
Five studies examined the association between global DNA methylation and BP 2 
(Table 1). Four of them used blood samples to assess DNA methylation and only 3 
one was conducted in VAT (20). Three of the five studies assessed global DNA 4 
methylation in the repeat sequences and transposable elements in the genome. 5 
A large portion of methylation sites within the genome is found in these 6 
sequences, and is shown to correlate with total genomic methylation content (21). 7 
Of these three, one study (reported in two articles) (16, 22) assessed both long-8 
interspersed nuclear element (LINE-1) and ALU transposable repeated elements, 9 
one study assessed solely LINE-1 methylation (20) and one solely ALU 10 
methylation (17). The remaining two studies assessed global DNA methylation 11 
as a percentage of total cytosine (methylcytosine/cytosine ratio) (23) or the level 12 
of 5-methylcytosine (5mC) (24). Two studies assessed BP as outcome, one study 13 
assessed hypertension and two additional studies (reported in three articles) (16, 14 
22, 23) assessed both BP and hypertension.  15 
The studies that assessed LINE-1 methylation showed and association of lower 16 
methylation level with higher diastolic blood pressure (DBP) and hypertension 17 
(16, 20, 22). From the two studies that assessed methylation of ALU transposable 18 
repeated elements, one showed results consistent with the previous two studies, 19 
lower ALU methylation with higher DBP (17), whereas the other study reported 20 
both systolic blood pressure (SBP) and DBP to be positively associated with the 21 
degree of methylation of the gene for ALU (16). 22 
Of the studies that measured methylcytosine, one reported higher levels of 5mC 23 
in healthy controls compared to patients with hypertension (24), whereas the 24 
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other one reported no association between methylcytosine/cytosine ratio and 1 
BP(23). 2 
Gene-specific DNA methylation and blood pressure 3 
 4 
Eighteen studies examined methylation sites in specific candidate genes (Table 5 
2).The rational and criteria for the selection of the candidate genes varied across 6 
studies. Some of the studies investigated genes (ADRB3, ABCG1, GALNT2 and 7 
HMGCR) that were previously identified in genome- or epigenome- wide 8 
association studies on hypertension or cardiovascular disease (18, 25, 26). Other 9 
investigations studied pro-inflammatory genes (TRl2, iNOS, IFNγ, F3, GCR, 10 
ICAM-1, TLR4, NFKB1, PPARγ and IL-6) (16, 17, 27-29), or renin-angiotensin-11 
system (RAS) genes (ACE promoter, and AGTR1) (30-33). Some others chose 12 
genes involved in the physiology of hypertension, e.g. related to the sympathetic 13 
nervous system, sodium homeostasis, extracellular fluid volume maintenance or 14 
proliferation of vascular smooth muscle cells (NET promoter, SCNN1A, ADD1 15 
and Mfn2) (34-38). 16 
Of the eighteen studies, one measured DNA methylation in VAT(20) and one in 17 
saliva (32), whereas the other studies used blood samples. Four of the studies 18 
did not report any level of adjustment or control for confounders, while the others 19 
controlled for age and additional confounders such as sex, body mass index, lipid 20 
levels, and smoking. Five studies assessed BP as outcome and twelve assessed 21 
hypertension. One additional study assessed both BP levels and hypertension as 22 
outcome (18). 23 
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Among the studies that assessed BP levels, three of them found hypomethylation 1 
of the genes (TLR4, ACE promoter and NFKB1) at higher levels of SBP (17, 28, 2 
30) and one found hypermethylation of the gene (ADRB3) at higher levels of SBP 3 
(25). There was also no consensus for DBP (Table S4). 4 
Overall, among the other 13 studies whose outcome was hypertension, 12 5 
studies found hypertension to be associated with hypomethylation of the 6 
candidate genes (ADD1, ADD1 promoter, GCK, AGTR1, IL-6, NET promoter, 7 
IFNγ promoter and Mfn2). Each of the genes ADD1 and AGTR1 were assessed 8 
by two studies, finding congruent results that showed hypomethylation in patients 9 
with hypertension (Table S4). Only one study found higher levels of methylation 10 
of the gene among hypertensive patients (39).  11 
Epigenome-wide analysis and blood pressure 12 
 13 
Three studies investigated genomic DNA methylation in a hypothesis-free 14 
approach (Table 3). One of them adjusted only for age and the other two, 15 
additionally, for sex, body mass index, and ethnicity, among others. The studies 16 
assessed DNA from blood and used replication cohorts to validate their findings. 17 
Wang et al., found seven out of the 10 differentially methylated top genes to be 18 
hypomethylated in American hypertensive patients (40). The top two CpG sites 19 
(one located in SULF1 and one in PRCP) could not be replicated in two 20 
independent cohorts. The study of Boström et al. was performed among patients 21 
that underwent gastric surgery. They found differentially methylated genes 22 
correlated with changes in SBP before and after the surgery. The association of 23 
the top CpGs with essential hypertension was evaluated (41). The replication 24 
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cohort showed two CpGs (one in EHMT2 and one in SKOR2) to be significantly 1 
hypomethylated in cases compared to controls.  2 
Finally, Richard et al. conducted a study using data from CHARGE consortium. 3 
After replication, 13 CpG sites were associated with BP. All replicated CpG sites 4 
demonstrated associations of decreased DNA methylation with increases in BP. 5 
The top CpG sites for both SBP and DBP were located at PHGDH locus and 6 
SLC7A11 locus (42). 7 
Histone modifications and blood pressure 8 
 9 
Only one study examined the association between histone modifications and BP 10 
(43). The authors assessed histone 3 acetylation and methylation levels in whole 11 
blood of Beijing workers and found higher levels of both acetylation and 12 
methylation associated with lower SBP and DBP. 13 
Discussion 14 
 15 
The present work is the first to systematically assess the current evidence of the 16 
association between epigenetic modifications and BP. We observed an 17 
association between a generalized hypomethylation status and high levels of 18 
DBP and SBP. Our findings suggest that epigenetic variations, mainly DNA 19 
methylation, may play an important role in the regulation of molecular 20 
mechanisms of BP. Accordingly, we showed that the genes reported in these 21 
findings are important regulators of inflammatory mechanisms (NFKB1, IFNγ, 22 
MFN2, SULF1), and RAS activity (PRCP, ACE, AGTR1 genes). However, no 23 
overlap was found between the findings from EWAs and the studies that used 24 
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candidate-gene approach. Conclusive evidence in alterations of histones in BP 1 
is still lacking. 2 
Global DNA methylation  3 
Global DNA methylation in DNA repetitive elements, such as ALU and LINE-1 4 
are the most widely used in population-based studies (44). There are 1.4 million 5 
ALU repetitive elements and half a million LINE-1 elements interspersed 6 
throughout the human genome, which represents up to 50% of global genomic 7 
methylation (45).  8 
Consistent trend of demethylation was observed with both LINE-1 and ALU. The 9 
studies that used LINE-1 concluded a significant association between decreased 10 
methylation levels and high SBP and DBP (16, 20, 22). Hypomethylation at ALU 11 
elements was related with higher BP (16). These findings are in line with other 12 
studies showing that hypomethylation at LINE-1, inversely correlates with 13 
coronary artery disease and stroke (11). In contrast, global DNA 14 
hypermethylation at LINE-1 appears to be associated with vascular inflammatory 15 
response to endothelial injury and increased mortality from chronic kidney 16 
disease (46).  17 
Gene-specific DNA methylation 18 
 19 
The assessment of DNA methylation in candidate genetic regions provides 20 
further insight into the importance of relevant genes and pathways in the aetiology 21 
of BP (47). Our review expands current knowledge of blood pressure-related 22 
pathways by supporting the role of (epi) genetic dysregulation of a specific set of 23 
genes in the development of abnormal BP levels. Several pieces of evidence 24 
Epigenetics and blood pressure: systematic review ⋯ 
13 
 
included in this review are consistent regarding the role of hypomethylation in 1 
ADD1 (Adducin1), AGTR1 (angiotensin II receptor type 1) and ACE (angiotensin 2 
I-converting enzyme) in the pathogenesis of hypertension.  3 
ADD1 is a protein coding gene, part of a family of cytoskeletal proteins (48), 4 
known to increase renal sodium reabsorption and involved in the pathophysiology 5 
of hypertension in the Asian population (49). The renin angiotensin system is a 6 
crucial mechanism in the aetiology of hypertension. The epigenetic variability 7 
found in genes involved in this system, such as AGTR1 and ACE, encourages 8 
the design of better approaches at both population and experimental level to get 9 
more insight into these mechanisms. 10 
Genetic factors of blood pressure regulation are still not very well elucidated. 11 
Evidence suggests a key role for 11β-hydroxysteroid dehydrogenase (11βHSD) 12 
on the pathogenesis of EH (50). Patients with EH show a decreased production 13 
of the enzyme, related with a prolonged half-life of cortisol and an increased ratio 14 
of urinary cortisol to cortisone metabolites. Genetic variants in the coding gene, 15 
HSD11B2, contribute to the enhanced blood pressure response to salt in humans 16 
(51). However, the percentage of people with essential hypertension is low and 17 
efforts have been focused in investigating overall blood pressure regulation and 18 
the influence of environmental factors. 19 
The evaluation of genes whose expression is associated with blood pressure may 20 
shed light on novel mechanisms associated with blood pressure regulation as 21 
well as unravel how transcripts mediate genetic and environmental effects on 22 
blood pressure variability (52). Huan et al. evaluated the global expression 23 
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signatures of blood pressure and hypertension in 7,017 individuals who were not 1 
receiving antihypertensive drug treatment. They identified 34 differentially 2 
expressed genes in relation to blood pressure, in which some of them explain 3 
5%–9% of inter-individual variance in blood pressure. The genes identified are 4 
involved in inflammatory response and apoptosis pathways (52).  5 
DNA methylation may differ by race or ethnicity, challenging replication across 6 
individuals of varying descent in epigenetic studies (53). Previous epigenome 7 
wide association studies of several cardio metabolic risk factors for example, C-8 
reactive protein, have been able to provide trans-ethnic replication of the 9 
differentially methylated genes (54). Current evidence supports the notion that 10 
despite differing baseline epigenetic profiles, different ethnicities may have 11 
consistent epigenetic association.  12 
Epigenome-wide association studies 13 
 14 
The implementation of EWAS, which are the large scale, systematic design, 15 
epigenome equivalent of GWAS, alongside with the development of microarray 16 
technologies, has allowed the interrogation of DNA methylation sites at single-17 
nucleotide resolution (55).  18 
In the current review, the three EWAS reported significantly hypomethylated 19 
CpGs in association with increase in BP (40-42). The hypomethylated CpG sites 20 
are located in the genes SULF1 (Sulfatase 1), PRCP (Prolylcarboxypeptidase), 21 
EHMT2 (Histone H3-K9 Methyltransferase 3), SKOR2 (SKI Family 22 
Transcriptional Corepressor 2), PHGDH (Phosphoglycerate Dehydrogenase) 23 
and SLC7A11 (Solute Carrier Family 7 Member 11). SULF1 is a protein coding 24 
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gene which catalyses the hydrolysis of the 6-O-sulfate group attached to 1 
glucosamine residues in heparin sulfate proteoglycans (56). The pathways 2 
controlled by this protein are closely related with inflammation through the 3 
production of interleukin-6 (57). PRCP gene encodes a member of the peptidase 4 
S28 involved in the degradation of angiotensin II, one of the main regulators of 5 
BP and electrolyte balance (58). EHMT2 encodes a methyltransferase that 6 
methylates lysine residues of histone H3 which is also associated with cellular 7 
responses to starvation, negative regulation of transcription from RNA 8 
polymerase II promoter and regulation of DNA replication (59, 60). SKOR2 gene 9 
is an homolog to the SKI family of transcriptional corepressors (61) and has been 10 
mainly identified as a potential tumour suppressor in neck squamous cell 11 
carcinomas (62). PHGDH encodes phosphoglycerate dehydrogenase, a key 12 
enzyme for de-novo sphingolipid synthesis, membrane lipids involved in lipid 13 
metabolism(63). SLC7A11 encodes a sodium-independent cysteine/glutamate 14 
antiporter resulting in protection from oxidative stress and ferroptotic cell death 15 
(64). Further research is needed to determine the functional relevance of EHMT2, 16 
SKOR2, PHGDH and SLC7A11 genes in the pathogenesis of hypertension.  17 
Age and gender-specific effects on epigenetic variations 18 
DNA methylation gradually changes with age while gender-specific methylation 19 
patterns have been observed over the lifespan (65). Several studies reported 20 
higher global DNA methylation levels in males (66), whereas studies on gender-21 
associated differences in DNA methylation at specific loci have yielded 22 
contrasting results (67). Among twenty studies, only three articles (with 23 
overlapping participants) stratified the analyses by gender (27, 31, 36). In 24 
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Chinese Han population, DNA methylation of ADD1 gene was significantly higher 1 
in females as compared to males, yet, ADD1 promotor methylation was a risk 2 
factor in both males (CpG2-5) and females (CpG1) (36). Similarly, AGTR1 CpG1 3 
methylation was a significant predictor of hypertension in both genders (31). 4 
Finally, at CpG1 and CpG2 sites of IL-6 promoter, males were hypomethylated 5 
as compared to females, yet, only hypomethylation of CpG3 site was significantly 6 
associated with hypertension risk in both genders (27). Gender stratification in 7 
epigenetics is lacking, as also seen in this review, thus we are not able to make 8 
any conclusions regarding the role of gender-specific methylation patterns in 9 
hypertension risk. 10 
In the context of aging, chronological age is one of the main determinants for 11 
functional impairments in blood pressure regulation. Until now, there is no 12 
evidence of the potential impact of the ‘epigenetic age’ on blood pressure. 13 
Considering that DNA methylation patterns change over time and are highly 14 
correlated with age, they may contribute to age-related traits such as blood 15 
pressure. Therefore, further research on the impact of ‘biological age’ on blood 16 
pressure variability is warranted. 17 
Strengths and limitations 18 
The strengths and limitations of the findings from this study merit careful 19 
consideration. The present analysis, involving data from nearly 28,382 20 
individuals, is the first to systematically assess the evidence on the subject 21 
following an a priori designed protocol with clearly defined inclusion and exclusion 22 
criteria. However, as mentioned above, the majority of studies included are cross-23 
sectional, making it difficult to determine whether epigenetic marks are a cause 24 
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or a consequence of BP. Moreover, many epigenetic studies are often limited by 1 
the fact that, since it is the most accessible tissue in epidemiologic studies, only 2 
blood is studied rather than other more relevant tissues. Although the use of 3 
standardized and validated protocols allowed us to undertake a comprehensive 4 
search of the literature, we cannot exclude the possibility of publication bias from 5 
underreporting negative findings. 6 
Conclusions 7 
The emerging evidence highlights the importance of epigenetic variation in the 8 
regulation and maintenance of blood pressure levels. The most convincing 9 
evidence has been reported from candidate-gene studies, where mechanisms 10 
related to RAS activation and inflammation can be assumed to represent a 11 
substrate for epigenetic regulation. Further studies integrating the systematic 12 
analysis of epigenetic markers at genomic scale, as well as the demonstration of 13 
the exact cellular and physiological role of target epigenetic modifications, will be 14 
needed to elucidate alternative molecular pathways. 15 
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Figure title and legend 1 
Fig 1. Flowchart of studies included in the systematic review. 2 
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Table 1. Global DNA methylation and blood pressure. 
 
Author, 
year, 
quality* 
Study 
design Outcome 
%male/Age/Sample size/ 
Country 
Methylation 
sites/ method Tissue 
type Adjustment level Main findings 
LINE-1 methylation      
Baccarelli 
et al., 
2010, 6/9 
(22) 
CS 
and PS Hypertension 100/55-92/n=712/USA 
Bisulfite PCR-
Pyrosequencing WB Age 
Inverse association. LINE-1 methylation was inversely 
associated with an existing diagnosis of hypertension 
at baseline (age-adjusted OR=0.6 [0.3 to 1.0] for 
subjects in the lowest vs. highest quartile-based 
category of LINE-1 methylation). 
Turcot et 
al., 2012, 
7/9 (20) 
CS Blood pressure 18.28/35.1±7.73/n=186/ Canada 
Bisulfite PCR-
Pyrosequencing VAT 
Age, sex, smoking, and waist 
circumference 
Inverse association. LINE-1 methylation was 
negatively associated with diastolic blood pressure (β 
=-0.65; p=0.03) after adjustments for the effects of 
age, sex, waist circumference and smoking. 
Alexeeff 
et al., 
2013, 7/9 
(16) 
CS 
and PS Blood pressure 
100/74.1±6.7**/n=789/ 
USA 
Bisulfite PCR-
Pyrosequencing WB 
Age, BMI, smoking, pack-years of 
smoking, DM, alcohol 
consumption, race, IHD or stroke, 
number of neutrophils in white 
blood count, season, and day of 
week. 
Inverse association. LINE-1 methylation was inversely 
associated with DBP (β=-0.7, 95% CI: -1.2, -0.2). The 
association with SBP was weaker, with the 95% CI 
including zero. 
ALU     
Alexeeff 
et al., 
2013, 7/9 
(16) 
CS 
and PS Blood pressure 
100/74.1±6.7**/n=789/ 
USA 
Bisulfite PCR-
Pyrosequencing WB 
Age, BMI, smoking, pack-years of 
smoking, DM, alcohol 
consumption, race, IHD or stroke, 
number of neutrophils in white 
blood count, season, and day of 
week. 
Positive association. ALU methylation was positively 
associated with both SBP and DBP. An increase in 
inter-quartile range (IQR) in the methylation was 
associated with an increase of 0.97mmHg in DBP 
(95% CI: 0.32–1.57) and with an increase of 
1.51mmHg in SBP (95% CI: 0.36-2.61). 
Bellavia 
et al., 
2013, 4/9 
(17) 
CS Blood pressure 53.3/27.7±8.6/ n=15/Canada 
TLR4, IL-12, IL-
6, iNOS/ Bisulfite 
PCR-
Pyrosequencing 
WB  
Inverse association. Decreased Alu methylation was 
associated with significantly increased DBP (β=0.41, 
p=0.04) and non-significantly increased SBP (β=0.40, 
p=0.15). 
5mC       
Smolarek 
et al., 
2010, 5/9 
(24) 
CC Essential hypertension 
63.33/ 36.74± 10.59/ 
n=90/Poland 
TLC analysis of 
the DNA 
nucleotide 
composition 
Blood 
Age, sex, BMI, duration of 
disease, smoking, concentration 
of cholesterol, ALT, AST, glucose, 
and others (not specified). 
Inverse association. The mean level of 5mC was 
1.80±0.69 in the healthy subjects, 1.14±0.48 in the 
whole group of patients with essential hypertension, 
1.29±0.50 in the patients with stage 1 hypertension, 
and 0.99±0.42 in patients with stage 2 hypertension. 
2 
 
CS: cross-sectional; PS: prospective; WB: whole blood; VAT: visceral adipose tissue; BMI: body mass index; DM: diabetes mellitus; IHD: ischemic heart disease; DBP: diastolic blood pressure; SBP: 
systolic blood pressure; CC: case-control; TLC: thin-layer chromatography; ALT: alanine aminotransferase; AST: aspartate aminotransferase; PBL: peripheral blood leukocytes.  
*Quality assessment based on the Newcastle-Ottawa Scale. Highest score: 9/9. 
**Mean age from the original cohort from which the patients were taken. 
 
mCyt/tCyt ratio       
Luttmer et 
al., 2013, 
7/9 (23) 
CS 
Blood 
pressure, 
hypertension 
49.5/68.7±7.2 /n=738/  
The Netherlands 
 Liquid 
chromatography–
tandem mass 
spectrometry. 
PBL 
 
Age, sex, and use of 
antihypertensive medication. 
No association. Mean systolic and diastolic blood 
pressure were not associated to MC/C ratio, nor was 
the presence of hypertension, with or without 
adjustment for antihypertensive treatment. 
Table 2. Gene-specific DNA methylation and blood pressure 
Author, year, 
quality* 
Study 
design Outcome 
Tissue 
type 
%male /Age/ 
Sample 
size/Country 
Methylation sites/ 
method 
Adjustment level 
 Main findings 
Bellavia et al., 
2013, 4/9 (17) CS 
Blood 
pressure WB 
53.3/27.7±8.6/ 
n=15/Canada 
TLR4/Bisulfite 
PCR-
Pyrosequencing 
 
Inverse association. Decreased TLR4 methylation was 
associated with significant increases of both diastolic (β=0.84, 
p=0.02) and systolic blood pressure (β=1.45, p=0.01). 
Alexeeff et al., 
2013, 7/9 (16) 
CS and 
PS 
Blood 
pressure WB 
100/74.1±6.7**/n=78
9/USA 
TRL2, iNOS, IFNγ, 
F3, GCR, ICAM-1/ 
Bisulfite PCR-
Pyrosequencing 
Age, BMI, smoking, 
pack-years of smoking, 
DM, alcohol 
consumption, race, IHD, 
number of neutrophils in 
with blood count, 
season, day of week. 
They found a positive association between DBP and 
methylation of TLR2 and iNOS, and a negative association 
between DBP and methylation of IFNγ. No clear associations 
were observed between SBP/DBP and methylation level of 
ICAM-1, GCR or F3. 
Zhang et al., 
2013, 6/9 (36) CC 
Essential 
hypertension 
(EH) 
PB 50.1/50.2±5.3/ n=61/China 
ADD1/Bisulfite 
PCR-
Pyrosequencing 
Adjusted for age, sex, 
smoking, and drinking.  
Inverse association. ADD1 CpG2-5 methylation levels were 
significantly associated with essential hypertension (cases 
versus controls (%): 27.54±7.48 versus 31.44±5.30, adjusted 
p=0.026). 
Guay et al., 
2014, 4/9 (25) CS 
Blood 
pressure VAT 100/-/n=30/Canada 
ADRB3/Bisulfite 
PCR-
Pyrosequencing 
 
Positive correlations. Partial Pearson´s correlations (r) 
between mean ADRB3 DNA methylation in visceral adipose 
tissue and SBP and DBP: r=0.43, p=0.05 and r=00.45, p=0.04, 
respectively. 
Peng et al., 
2014, 8/9 (26) CS Hypertension PB 
64/59.39±9.14/ 
n=139/China 
ABCG1, GALNT2, 
HMGCR/ Bisulfite 
PCR-
Pyrosequencing 
Age, sex, smoking, lipid 
level, history of 
hypertension and 
history of diabetes. 
Treating gene methylation as a dichotomous variable 
(methylated or unmethylated), none statistically significant 
difference was found between patients with or without 
hypertension. 
Rangel et al., 
2014, 7/9 (30) CS 
Blood 
pressure PBL 
52/8.99±0.22/ 
n=115/Brazil 
ACE promoter/ 
Bisulfite PCR-
Pyrosequencing 
Age, sex, birth weight, 
prematurity and family 
history of CVD. 
Inverse association. Hypomethylation of the ACE promoter 
was associated with changes in SBP as well as ACE activity, 
even after adjustment for confounders. Pearson´s correlation 
coefficient: -0.206, p=0.031. 
Fan et al., 
2015, 6/9 (33) CC 
Essential 
hypertension PB 
M and W***/ 
59.28±7.41/ 
n=94/China 
GCK, 4CpGs/ 
Bisulfite PCR-
Pyrosequencing 
Age-matched 
Significantly lower CpG 1-3 methylation (cases vs. controls, 
49.13±5.72 vs. 53.49±7.53%; adjusted p=0.006) and 
significantly higher CpG4 methylation (cases vs. controls, 
46.34±6.48 vs. 34.74±12.73%; adjusted p=0.002) were 
observed in patients with hypertension.  
Kato et al., 
2015, 6/9 (18) CS 
SBP, DBP, 
and 
hypertension  
PB 
74.2/54.6± 9.99/ 
n=6,757/South 
Asian and European 
population.  
28 CpG/Bisulfite 
PCR-
Pyrosequencing 
 
Based on their GWAS analysis on five blood pressure 
phenotype, 35 sentinel SNPs were identified. Then, they 
investigated the relationship of them with local DNA 
methylation and found that 28 of the 35 SNPs were associated 
with local methylation markers. Then, using Mendelian 
randomization, they showed that the observed effects of SNPs 
on blood pressure were correlated with the effects predicted 
through association with methylation (r=0.52, p=0.005). 
Fan et al., 
2015, 7/9 (31) CC 
Essential 
hypertension 
(EH) 
PB 40/ 56.52±8.47/ n=192/China 
AGTR1 promoter, 
5 CpGs/Bisulfite 
PCR-
Pyrosequencing 
Age, gender, smoking, 
drinking, BMI, 
triglycerides, HDL, uric 
acid and homocysteine. 
Inverse association. A significantly lower CpG1 methylation 
level was identified in EH cases compared to controls (cases 
vs. controls: 6.74 ± 4.32% vs. 9.66 ± 5.45%, p = 0.007), and 
no significant association was observed in the remaining 
analyses. Receiver operating characteristic curves showed 
that CpG1 methylation was a significant predictor of EH. 
Mao et al., 
2016, 7/9 (35) CC 
Essential 
hypertension 
(EH) 
PB 35/ 57.83±7.74/ n=180/China 
SCNN1A/Bisulfite 
PCR-
Pyrosequencing 
Age, sex, gender, BMI, 
TC, TG, glucose, ALT, 
smoking and drinking. 
Positive association. Incident cases had a higher SCNN1A 
methylation level than the non-EH controls (16.15±4.51 versus 
13.66±4.08, p=0.041) and prevalent cases (16.15±4.51 versus 
13.77±3.90, p=0.002). Logistic regression analysis results 
showed that SCNN1A hypermethylation was the risk factor of 
EH in incident cases compared with non-EH (OR=1.157, 
p=0.01), and in incident cases compared with prevalent cases 
(OR=1.149, p=0.013). 
Bayoumy et 
al., 2017, 5/9 
(37) 
CC 
Essential 
hypertension 
(EH) 
WB 48/52.6±5.02/ n=250/Egypt 
ADD1 promoter/ 
Bisulfite PCR-
Pyrosequencing 
 
Inverse association. Lower methylation of AAD1 CpG2-5 was 
found among EH cases (29.21±6.81) compared to the healthy 
group (34.63±7.5). 
Lin et al., 
2017, 6/9 (32) CC 
Essential 
hypertension Saliva 
51.4/40.76± 16.92*/ 
n=326/China 
AGTR1/Bisulfite 
PCR-
Pyrosequencing 
Age, sex, education 
level, marital status, 
physical activity, diet 
regularity, smoking and 
drinking status, and 
sleep duration and 
quality. 
Inverse association.  There was a decrease in DNA 
methylation in the hypertensive group compared to the control 
group.  
CS: cross-sectional; WB: whole blood; PS: prospective; BMI: body mass index; DM: diabetes mellitus; IHD: ischemic heart disease; DBP: diastolic blood pressure; SBP: systolic blood pressure; CC: 
case-control; PB: peripheral blood; VAT: visceral adipose tissue; PBL: peripheral blood leukocytes; CVD: cardiovascular disease; M: men; W: women; HDL: high-density-lipoprotein; TC: total cholesterol; 
TG: triglycerides; ALT: alanine aminotransferase; PBMC: peripheral blood mononuclear cells; PMR: percentage of methylated reference. 
*Quality assessment based on the Newcastle-Ottawa Scale. Highest score: 9/9. 
**Mean age from the original cohort from which the patients were taken. 
***Percentage of men not described.  
Mao et al., 
2017, 6/9 (27) CC 
Essential 
hypertension 
(EH) 
PB 40/ 56.5± 8.5/ n=192/China 
IL-6/Bisulphite 
pyrosequencing 
Age- and gender-
matched 
Inverse association. CpG2 and CpG3 had lower methylation in 
EH group compared with controls (58.43 ± 7.53 versus 62.34 ± 
9.65, p=0.004 and 51.52 ± 6.18 versus 57.45 ± 8.29, p<0.001, 
respectively). Logistic regression analysis found that CpG3 
hypomethylation was a risk factor of EH (OR= 1.11, adjusted 
p=0.004). Receiver operating characteristic curve analysis 
showed that CpG2 (area under the curve: 0.638, p=0.001) and 
CpG3 (area under the curve: 0.704, p<0.001) had a diagnostic 
value to predict the risk of EH. 
Meng et al., 
2017, 6/9 (34) CS Hypertension PBL 
85.4/ 45.1±7.43/ 
n=162/China 
NET promoter/ 
Pyrophosphate 
sequencing 
Age and BMI 
Inverse association. The average and specific methylation 
levels were higher in non-hypertensive subjects except for 
CpG2. 
Bao et al., 
2018, 6/9 (29) CC 
Essential 
hypertension 
(EH) 
PB 39.6/ 56.5±8.43/ n=192/China 
IFNγ promoter, 6 
CpGs/ 
pyrosequencing 
Age, sex, smoking, 
drinking, uric acid, HDL 
and BMI 
CpG2 was significantly hypomethylated among cases 
compared controls (p=0.032) and it was found to be an effective 
marker of EH based on the area under the curve.  
Jin et al., 
2018, 7/9 (38) CC 
Essential 
hypertension 
WB or 
serum 
59.2/ 50.6±2.54/ 
n=76/China 
Mfn2/ Bisulphite 
DNA sequencing Age- and sex-matched 
The DNA methylation level of Mfn2 was significantly lower in 
hypertensive patients than in controls.  
Macías-
González et 
al., 2018, 6/9 
(28) 
PS Blood pressure PBMC 
34.6/ 44.68±9.27/  
n=60/Spain 
PPARγ, SLC19A1, 
IL-6, NFKB1/ 
pyrosequencing 
Age, sex, bariatric 
procedure, weight loss 
(%) 
There was no statistically significant difference between the 
DNA methylation patterns of the PPARγ, SLC19A1 and IL-6 
genes before and 6 months after bariatric surgery. The 
promoter methylation levels of the NFKB1 gene were increased 
after surgery. This change of methylation level was associated 
with changes in both SBP and DBP (r=-0.513, p=0.003 and r=-
0.544, p=0.002, respectively). 
Xu et al., 
2018, 6/9 (39)  CC 
Essential 
hypertension Serum 
53.3/ 65.9±9.2 
/n=461/China 
MTHFD1 
promoter/ 
methylation-
specific PCR 
Age, gender, total 
homocysteine, uric acid, 
TG, BMI, glucose, waist 
circumference, hip 
circumference, SBP, 
DBP, drinking, smoking. 
The MTHFD1 promoter methylation was higher in hypertensive 
patients than healthy controls (median PMR were 8.97% and 
5.69%, respectively, p<0.001). Multivariable analysis showed 
that MTHFD1 promoter hypermethylation increases the risk of 
essential hypertension (OR=1.336; 95% CI: 1.235, 1.446; p< 
0.001). The area under the curve of MTHFD1 promoter 
methylation was 0.739 in total patients with essential 
hypertension. 
Table 3. Epigenome-wide association and histone modification in relation to blood pressure. 
Author, year, 
quality* 
Study 
design Outcome 
Tissue 
type 
%male/Age/ 
Sample 
size/Country 
Methylation sites/ 
method 
Adjustment level 
 Main findings 
Epigenome-Wide Association Study     
Wang et al., 
2013, 6/9 (40) CC 
Essential 
Hypertension 
(EH) 
PB 100/14-23/n=16/ USA 
Illumina 
HumanMethylation 27K 
BeadChip 
Age 
7 out of the 10 most significant CpG sites were hypomethylated in 
cases. The two most significant CpGs (one CpG site in SULF1 gene 
and one in PRCP gene) were replicated in 96 patients. CpG in 
SULF1 remained significant even after adjustment for age 
(p=0.038). Validation of the CpG sites in the SULF1 gene was further 
conducted in a second replication sample of 70 patients and it was 
not found to be significantly different methylated among cases vs 
controls.  
Boström et 
al., 2016, 6/9 
(41) 
CS and 
PS 
Blood 
pressure and 
essential 
hypertension 
(EH) 
WB 49.8/46.9±11.9/n=11/Switzerland 
Illumina 
HumanMethylation 
450K BeadChip 
Age, sex, BMI and 
ethnicity.  
In case of 24 CpG sites, changes in methylation was significantly 
correlated with the percentile change in SBP six months after RYGB 
surgery. Those CpG were further investigated for an association with 
EH in the verification cohort (n=539, aged 19 to 101 years), finding 
two CpG (one in EHMT2 and one in SKOR2) significantly 
hypomethylated in EH.  
Richard et al., 
2017, 8/9 (42) CS 
Blood 
pressure 
(BP) 
WB 
and 
CD4+ 
T 
cells** 
M and W***/ 
mean age 
between 46.3 
and 
76.0/n=17,010/C
onsortia 
Illumina 
HumanMethylation 
450K BeadChip 
Age, sex, blood cell 
counts, BMI, smoking, 
ancestry and technical 
covariates. 
In the discovery stage, they conducted genome-wide associations of 
DNA methylation with SBP and DBP in nine cohort studies 
(n=9,828). Multiethnic meta-analyses identified methylation at 31 
CpG sites associated with BP after Bonferroni correction. They 
replicated those 31 CpG in multiethnic meta-analyses of six 
additional cohorts (n=7,182). Methylation at 13 of the 31 discovery 
CpG sites (corresponding to 8 genes) was associated with BP at 
p<0.0016 in the replication meta-analysis (0.05/31). All of the 13 
CpG demonstrated associations of decreased DNA methylation with 
increases in BP. The top CpG sites for both SBP and DBP were 
located at PHGDH locus and SLC7A11 locus. The investigators 
found a mediation of a causal relationship of cg23999170 with BP 
through expression of TSPAN2. 
Histone modification      
CC: case-control; PB: peripheral blood; CS: cross-sectional; PS: prospective; WB: whole blood; BMI: body mass index; RYGB: Roux-en-Y gastric bypass surgery; M: men; W: women; SBP: systolic 
blood pressure; DBP: diastolic blood pressure. 
*Quality assessment based on the Newcastle-Ottawa Scale. Highest score: 9/9. 
**Of the 14 cohorts, 13 used whole blood samples to measure DNA methylation. One cohort (GOLDN) used CD4+ T cells. 
***Percentage of men not described.  
 
 
Kresovich et 
al., 2017, 6/9 
(43) 
CS Blood pressure WB 
67/18-46/ 
n=240/China 
Histone 3 lysine 9 
acetylation (H3K9ac), 
histone 3 
lysine 9 tri-methylation 
(H3K9me3), histone 3 
lysine 27 tri-methylation 
(H3K27me3), and 
histone 3 lysine 36 tri-
methylation 
(H3K36me3) 
Age, sex, occupational 
group, BMI, work 
hours per week, day of 
the week, smoking 
habits, number of 
cigarettes smoked 
during examination 
time, alcohol drinking 
status, temperature, 
and 8-day ambient 
PM10. 
Inverse association. In all participants, a one fold increase in H3K9ac 
was associated with 2.52mmHg lower mean SBP (95%CI: -4.22, -
0.81, p<0.01) and 1.54 mmHg lower mean MAP (95%CI: -2.95, -
0.14, p=0.03). A one-fold increase in H3K9me3 was associated with 
2.04mmHg lower mean SBP (95%CI: -3.32, -0.77, p<0.01), 1.68 
mmHg lower mean DBP (95%CI: -2.84, -0.52, p=0.01), and 1.75 
mmHg lower mean MAP (95%CI:-2.86, - 0.64, p<0.01). Finally, the 
authors observed a one-fold increase in H3K27me3 associated with 
2.2 8mmHg lower SPB (95%CI:-4.42, -0.13, p=0.04). 
